title: Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia. A randomized, placebo-controlled study.
abstract: OBJECTIVE
  To assess the safety and efficacy of aerosol pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome (AIDS).
  
  
  METHODS
  Patients recovering from a first confirmed episode of AIDS-related P. carinii pneumonia who had no evidence of either another active AIDS-defining opportunistic infection or another pulmonary abnormality were considered eligible for the study but were included only if they had received no immunomodulators or antiretroviral agents other than zidovudine within 30 days of entry. One hundred sixty-two patients were randomized and started on the study drug.
  
  
  METHODS
  Patients were randomly assigned to receive aerosol pentamidine, 60 mg per dose, or placebo, delivered using a hand-held, patient-triggered, ultrasonic nebulizer. The induction phase of treatment consisted of 5 doses over 14 days, followed by a maintenance phase beginning on day 21 and consisting of one dose every 2 weeks.
  
  
  RESULTS
  Thirty-two cases of P. carinii pneumonia were diagnosed before the termination of the trial; 27 cases occurred among 78 patients receiving placebo and 5 occurred among 84 patients receiving aerosol pentamidine. Estimates of the cumulative relapse rate of P. carinii pneumonia by 24 weeks were 50% and 9% for the placebo and pentamidine groups, respectively (P less than 0.001). Adverse reactions attributed to the study drug occurred in 15 of 78 patients receiving placebo and in 28 of 84 patients receiving pentamidine (P = 0.04). These were all mild or moderate in severity and did not preclude continued administration of the study drug.
  
  
  CONCLUSIONS
  Intermittent therapy with aerosol pentamidine is highly effective and well tolerated as secondary prophylaxis for AIDS-related P. carinii pneumonia.
authors.affiliation: St. Paul's Hospital, Vancouver, British Columbia.
authors.forename: J S
authors.initials: JS
authors.lastname: Montaner
authors.forename: L M
authors.initials: LM
authors.lastname: Lawson
authors.forename: A
authors.initials: A
authors.lastname: Gervais
authors.forename: R H
authors.initials: RH
authors.lastname: Hyland
authors.forename: C K
authors.initials: CK
authors.lastname: Chan
authors.forename: J M
authors.initials: JM
authors.lastname: Falutz
authors.forename: P M
authors.initials: PM
authors.lastname: Renzi
authors.forename: D
authors.initials: D
authors.lastname: MacFadden
authors.forename: A R
authors.initials: AR
authors.lastname: Rachlis
authors.forename: I W
authors.initials: IW
authors.lastname: Fong
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy; D000328:Adult; D000336:Aerosols; D001986:Bronchial Spasm / Q000139:chemically induced; D003371:Cough / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010419:Pentamidine / Q000008:administration & dosage* / Q000009:adverse effects; D010919:Placebos; D011020:Pneumonia, Pneumocystis / Q000209:etiology / Q000517:prevention & control*; D012008:Recurrence; D013223:Statistics as Topic; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D000336:Aerosols; D010919:Placebos; D015215:Zidovudine; D010419:Pentamidine